854.16 USD
+2.44 (+0.29%)
Last: Feb 4, 2026, 10:10 AM
Overall ARGX gets a fundamental rating of 6 out of 10. We evaluated ARGX against 524 industry peers in the Biotechnology industry. ARGX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ARGX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make ARGX suitable for growth investing!
1. Profitability
1.1 Basic Checks
- ARGX had positive earnings in the past year.
- In the past year ARGX had a positive cash flow from operations.
- ARGX had negative earnings in 4 of the past 5 years.
- ARGX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- ARGX has a Return On Assets of 17.84%. This is amongst the best in the industry. ARGX outperforms 96.37% of its industry peers.
- With an excellent Return On Equity value of 21.00%, ARGX belongs to the best of the industry, outperforming 96.18% of the companies in the same industry.
- ARGX's Return On Invested Capital of 6.01% is amongst the best of the industry. ARGX outperforms 92.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROIC | 6.01% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 41.97%, ARGX belongs to the top of the industry, outperforming 97.52% of the companies in the same industry.
- Looking at the Operating Margin, with a value of 15.30%, ARGX belongs to the top of the industry, outperforming 93.32% of the companies in the same industry.
- Looking at the Gross Margin, with a value of 89.40%, ARGX belongs to the top of the industry, outperforming 91.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ARGX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for ARGX has been increased compared to 1 year ago.
- The number of shares outstanding for ARGX has been increased compared to 5 years ago.
- The debt/assets ratio for ARGX is higher compared to a year ago.
2.2 Solvency
- ARGX has an Altman-Z score of 30.71. This indicates that ARGX is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of ARGX (30.71) is better than 92.75% of its industry peers.
- ARGX has a debt to FCF ratio of 0.14. This is a very positive value and a sign of high solvency as it would only need 0.14 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 0.14, ARGX belongs to the top of the industry, outperforming 95.61% of the companies in the same industry.
- ARGX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
- ARGX has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: ARGX outperforms 46.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Altman-Z | 30.71 |
ROIC/WACC0.81
WACC7.43%
2.3 Liquidity
- ARGX has a Current Ratio of 5.60. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
- ARGX has a Current ratio (5.60) which is comparable to the rest of the industry.
- A Quick Ratio of 5.27 indicates that ARGX has no problem at all paying its short term obligations.
- ARGX has a Quick ratio (5.27) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 |
3. Growth
3.1 Past
- ARGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1512.50%, which is quite impressive.
- The Revenue has grown by 64.71% in the past year. This is a very strong growth!
- The Revenue has been growing by 94.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
Revenue 1Y (TTM)64.71%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%95.51%
3.2 Future
- ARGX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 105.80% yearly.
- ARGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 35.42% yearly.
EPS Next Y934.93%
EPS Next 2Y316.29%
EPS Next 3Y180.77%
EPS Next 5Y105.8%
Revenue Next Year95.19%
Revenue Next 2Y63.47%
Revenue Next 3Y48.27%
Revenue Next 5Y35.42%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 63.98, ARGX can be considered very expensive at the moment.
- ARGX's Price/Earnings ratio is rather cheap when compared to the industry. ARGX is cheaper than 90.46% of the companies in the same industry.
- ARGX is valuated expensively when we compare the Price/Earnings ratio to 28.18, which is the current average of the S&P500 Index.
- ARGX is valuated quite expensively with a Price/Forward Earnings ratio of 26.54.
- 92.37% of the companies in the same industry are more expensive than ARGX, based on the Price/Forward Earnings ratio.
- When comparing the Price/Forward Earnings ratio of ARGX to the average of the S&P500 Index (25.51), we can say ARGX is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 63.98 | ||
| Fwd PE | 26.54 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ARGX indicates a rather cheap valuation: ARGX is cheaper than 89.89% of the companies listed in the same industry.
- 91.03% of the companies in the same industry are more expensive than ARGX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 171.22 | ||
| EV/EBITDA | 96.11 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as ARGX's earnings are expected to grow with 180.77% in the coming years.
PEG (NY)0.07
PEG (5Y)N/A
EPS Next 2Y316.29%
EPS Next 3Y180.77%
5. Dividend
5.1 Amount
- No dividends for ARGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:ARGX (2/4/2026, 10:10:10 AM)
854.16
+2.44 (+0.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-26 2026-02-26/amc
Inst Owners43.42%
Inst Owner Change2.57%
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap52.86B
Revenue(TTM)3.60B
Net Income(TTM)1.28B
Analysts84
Price Target1030.03 (20.59%)
Short Float %2.76%
Short Ratio4.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.16%
Min EPS beat(2)7.11%
Max EPS beat(2)23.2%
EPS beat(4)3
Avg EPS beat(4)3962.36%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)1996.71%
EPS beat(12)8
Avg EPS beat(12)1343.38%
EPS beat(16)12
Avg EPS beat(16)1012.62%
Revenue beat(2)1
Avg Revenue beat(2)3.68%
Min Revenue beat(2)-0.81%
Max Revenue beat(2)8.17%
Revenue beat(4)3
Avg Revenue beat(4)5.02%
Min Revenue beat(4)-0.81%
Max Revenue beat(4)8.17%
Revenue beat(8)6
Avg Revenue beat(8)5.96%
Revenue beat(12)10
Avg Revenue beat(12)14.45%
Revenue beat(16)13
Avg Revenue beat(16)17.87%
PT rev (1m)5.89%
PT rev (3m)18.86%
EPS NQ rev (1m)-0.25%
EPS NQ rev (3m)-0.25%
EPS NY rev (1m)-0.56%
EPS NY rev (3m)13.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.34%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 63.98 | ||
| Fwd PE | 26.54 | ||
| P/S | 17.33 | ||
| P/FCF | 171.22 | ||
| P/OCF | 130.92 | ||
| P/B | 8.67 | ||
| P/tB | 8.99 | ||
| EV/EBITDA | 96.11 |
EPS(TTM)13.35
EY1.56%
EPS(NY)32.19
Fwd EY3.77%
FCF(TTM)4.99
FCFY0.58%
OCF(TTM)6.52
OCFY0.76%
SpS49.3
BVpS98.5
TBVpS94.97
PEG (NY)0.07
PEG (5Y)N/A
Graham Number172.01
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.84% | ||
| ROE | 21% | ||
| ROCE | 7.61% | ||
| ROIC | 6.01% | ||
| ROICexc | 16.72% | ||
| ROICexgc | 18.56% | ||
| OM | 15.3% | ||
| PM (TTM) | 41.97% | ||
| GM | 89.4% | ||
| FCFM | 10.12% |
ROA(3y)-5.23%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.14 | ||
| Debt/EBITDA | 0.07 | ||
| Cap/Depr | 428.74% | ||
| Cap/Sales | 3.12% | ||
| Interest Coverage | 519.07 | ||
| Cash Conversion | 82.6% | ||
| Profit Quality | 24.11% | ||
| Current Ratio | 5.6 | ||
| Quick Ratio | 5.27 | ||
| Altman-Z | 30.71 |
F-Score6
WACC7.43%
ROIC/WACC0.81
Cap/Depr(3y)176.19%
Cap/Depr(5y)545.91%
Cap/Sales(3y)10.66%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1512.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%272.66%
EPS Next Y934.93%
EPS Next 2Y316.29%
EPS Next 3Y180.77%
EPS Next 5Y105.8%
Revenue 1Y (TTM)64.71%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%95.51%
Revenue Next Year95.19%
Revenue Next 2Y63.47%
Revenue Next 3Y48.27%
Revenue Next 5Y35.42%
EBIT growth 1Y208.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1529.77%
EBIT Next 3Y219.36%
EBIT Next 5Y122.96%
FCF growth 1Y140.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y161.76%
OCF growth 3YN/A
OCF growth 5YN/A
ARGENX SE - ADR / ARGX FAQ
What is the fundamental rating for ARGX stock?
ChartMill assigns a fundamental rating of 6 / 10 to ARGX.
What is the valuation status for ARGX stock?
ChartMill assigns a valuation rating of 6 / 10 to ARGENX SE - ADR (ARGX). This can be considered as Fairly Valued.
Can you provide the profitability details for ARGENX SE - ADR?
ARGENX SE - ADR (ARGX) has a profitability rating of 5 / 10.
What are the PE and PB ratios of ARGENX SE - ADR (ARGX) stock?
The Price/Earnings (PE) ratio for ARGENX SE - ADR (ARGX) is 63.98 and the Price/Book (PB) ratio is 8.67.
What is the earnings growth outlook for ARGENX SE - ADR?
The Earnings per Share (EPS) of ARGENX SE - ADR (ARGX) is expected to grow by 934.93% in the next year.